Biggest News Aggregation in the World

Page 4 - Why Target News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Why Target. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Why Target Today - Breaking & Trending Today

Calliditas Therapeutics: Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO (budesonide) in IgA Nephropathy

Published: October 19, 2022

STOCKHOLM, Oct. 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful

Source: finanznachrichten.de

Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy

Published: October 19, 2022

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the...

Source: prnewswire.com

Calliditas Therapeutics Launches an Online Patient

Published: May 14, 2022

This launch coincides with the inaugural IgAN Awareness Day...

Source: globenewswire.com

Calliditas Therapeutics Launches an Online Patient Platform

Published: May 14, 2022

14.05.2022 - This launch coincides with the inaugural IgAN Awareness DaySTOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) - Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new ...

Source: wallstreet-online.de

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Published: March 14, 2022

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...